BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -239.20K | -401.30K | -455.50K | -290.20K | -299.00K |
| Total Depreciation and Amortization | 41.80K | 42.60K | 42.20K | 74.80K | 72.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.40K | 93.90K | 166.80K | 6.70K | 23.50K |
| Change in Net Operating Assets | 40.30K | 168.90K | 12.10K | 49.70K | -169.60K |
| Cash from Operations | -135.60K | -95.80K | -234.40K | -159.10K | -372.20K |
| Capital Expenditure | 0.00 | 0.00 | -1.80K | -900.00 | -1.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | 0.00 | -1.80K | -900.00 | -1.60K |
| Total Debt Issued | 110.30K | 89.30K | 89.30K | 89.30K | 89.30K |
| Total Debt Repaid | -122.00K | -116.40K | -155.40K | -379.90K | -419.10K |
| Issuance of Common Stock | 255.40K | 51.00K | 373.90K | 350.00K | 983.10K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 174.20K | 17.50K | 224.90K | 44.10K | 480.10K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 38.50K | -78.20K | -11.20K | -115.90K | 106.30K |